CoChat

Durability of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Booster Vaccine Protection Against Omicron Among Healthcare Workers With a Vaccine Mandate

Open access
Richterman, Aaron, Behrman, Amy, Brennan, Patrick J, O’Donnell, Judith A, Snider, Christopher K, Chaiyachati, Krisda H · 2023 · Clinical Infectious Diseases
Cited by 24

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has spread rapidly throughout the world since being identified in South Africa in November 2021. Few studies have assessed primary series and booster vaccine effectiveness against Omicron among US healthcare workers Methods: We conducted a test-negative case-control design to estimate BNT162b2 and mRNA1273 primary vaccination and booster effectiveness against SARS-CoV-2 infection and symptomatic coronavirus disease 2019 during an Omicron surge among employees of the University of Pennsylvania Health System. The study period was between 1 July 2021 and 5 April 2022. We defined the Delta period as 1 July to 12 December 2021 and the Omicron period as beginning 12 December 21. Results: Our sample included 14 520 tests (2776 [19%] positive)—7422 (506 [7%] positive) during Delta and 7098 (2270 [32%] positive) during Omicron. Benchmarked against Delta, the vaccine effectiveness of 2 vaccine doses was lower during Omicron, with no significant protection against infection. Booster doses added significant protection, although they also showed reduced effectiveness during Omicron. Compared with findings in employees who had received 2 vaccine doses, 3 doses of BNT162b2 had a relative effectiveness of 50% (95% confidence interval, 42%–56%) during Omicron, relative to 78% (63%–87%) during Delta; 3 doses of mRNA1273 had a relative effectiveness of 56% (45%–65%) during Omicron, relative to 96% (82%–99%) during Delta. Restricting the sample to symptomatic tests yielded similar results to our primary analysis. After initial waning in BNT162b2 booster protection against infection, it remained largely stable for ≥16 weeks after vaccination. Conclusions: Our findings provide a strong rationale for boosters among healthcare workers in the Omicron era.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciac454

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 12

  1. Lyngse, 2021, SARS-CoV-2 omicron VOC transmission in Danish households, 10.1101/2021.12.27.21268278 · DOI
  2. Accorsi, 2022, Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants, JAMA, 327, 639, 10.1001/jama.2022.0470 · DOI · Paper page
  3. Andrews, 2022, Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant, N Engl J Med, 386, 1532, 10.1056/NEJMoa2119451 · doi:10.1056/nejmoa2119451 · Paper page
  4. Gooch, Hospitals, health systems mandating vaccines for workers: Becker’s hospital review
  5. Mahraj, 2021, Developing a large-scale Covid-19 surveillance system to reopen campuses, 10.1056/CAT.21.0049 · DOI
  6. Baden, 2021, Phase 3 trial of mRNA-1273 during the Delta-variant surge, N Engl J Med, 385, 2485, 10.1056/NEJMc2115597 · DOI · Paper page
  7. Chemaitelly, 2022, Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar, 10.1101/2022.02.07.22270568 · DOI · Paper page
  8. Klompas, 2022, Preventing SARS-CoV-2 transmission in health care settings in the context of the Omicron variant, JAMA, 327, 619, 10.1001/jama.2022.0262 · DOI
  9. Richterman, 2020, Hospital-acquired SARS-CoV-2 infection: lessons for public health, JAMA, 324, 2155, 10.1001/jama.2020.21399 · doi:10.1001/jama.2020.21399
  10. Yu, 2022, Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants, N Engl J Med, 386, 1579, 10.1056/NEJMc2201849 · DOI · Paper page
  11. Lyngse, 2022, Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish households, 10.1101/2022.01.28.22270044 · DOI
  12. Kirsebom, 2022, COVID-19 vaccine effectiveness against the Omicron BA.2 variant in England, 10.1016/S1473-3099(22)00309-7 · DOI · Paper page

Cited by

Metadata

Authors
Richterman, A., Behrman, A., Brennan, P. J., O’Donnell, J. A., Snider, C. K., & Chaiyachati, K. H.
Venue
Clinical Infectious Diseases
Published
2022-07-06
Volume
76
Issue
3
Pages
e319-e326
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W4282943565
Cited by
24
References
7
FWCI
2.72
Type
journal article
Language
en
Open access
green
Funders
National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.